Neutralizing Antibody Market Report 2026

The neutralizing antibody market size has grown rapidly in recent years. It will grow from $257.81 billion in 2025 to $288.51 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to emergence of viral outbreaks like sars-cov-2, development of early monoclonal antibody platforms, increasing r&d in immunology, adoption of antibodies in diagnostic assays, reliance on animal-derived polyclonal antibodies.

The neutralizing antibody market size is expected to see rapid growth in the next few years. It will grow to $447.16 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to advancements in fully human and humanized monoclonal antibodies, growth in recombinant polyclonal antibody technology, rising global demand for COVID-19 and influenza therapeutics, increasing collaboration between pharma and biotech companies, expansion of antibody research in emerging markets. Major trends in the forecast period include rising investment in neutralizing antibody therapeutics, expansion of monoclonal and polyclonal antibody development, increasing applications in viral diagnostics and research, growing focus on personalized medicine and targeted therapies, enhanced regulatory oversight and compliance for antibody production.

The increasing prevalence of infectious diseases is anticipated to drive the growth of the neutralizing antibody market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, that can spread directly or indirectly between individuals. The rise in infectious diseases is largely attributed to increased global travel, which accelerates the cross-border transmission of pathogens. Neutralizing antibodies support the treatment of infectious diseases by precisely targeting and blocking pathogens, thereby preventing disease progression. They enhance patient outcomes by offering timely and targeted immune protection. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government organization, tuberculosis cases in England increased to 4,850 in 2023, representing a 10.7% rise from 4,380 cases in 2022. Therefore, the rising prevalence of infectious diseases is fueling the growth of the neutralizing antibody market.

Major companies operating in the neutralizing antibody market are concentrating on the development of innovative therapies, such as long-acting monoclonal neutralizing antibodies, to deliver sustained protection against infectious diseases, address unmet needs among vulnerable populations, and overcome limitations associated with conventional vaccines. Long-acting monoclonal neutralizing antibodies are engineered proteins that bind viral antigens with high specificity to block infection, while engineered modifications to the Fc region extend their duration of action in the body. Unlike traditional small-molecule antivirals or vaccines, these antibodies provide passive immunity without requiring frequent dosing or activation of the recipient’s immune system. For example, in June 2025, Merck & Co. Inc., a US-based pharmaceutical company, introduced clesrovimab-cfor, a long-acting monoclonal neutralizing antibody approved by the U.S. Food and Drug Administration. This fully human IgG1κ antibody targets the fusion (F) protein of respiratory syncytial virus (RSV) and incorporates a triple amino acid substitution in its Fc region to improve binding to the neonatal Fc receptor and extend serum half-life. Delivered as a single 105 mg intramuscular injection irrespective of infant weight, it offers season-long protection against RSV, supporting preventive care for infants and high-risk groups.

In February 2023, Vir Biotechnology Inc., a US-based commercial-stage immunology company, entered into a partnership with GSK to continue the discovery and development of next-generation therapies for COVID-19 and other respiratory illnesses. Through this collaboration, Vir seeks to maintain access to sotrovimab while advancing its pipeline of monoclonal antibody treatments targeting respiratory viruses. GSK plc is a UK-based pharmaceutical company focused on innovative therapies in infectious diseases and immunology.

Major companies operating in the neutralizing antibody market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., GeNext Genomics, Celltrion Healthcare Co. Ltd, BeiGene Ltd, AbCellera Biologics Inc., BMC Pharmacology and Toxicology, Anthos Therapeutics, Immunome Inc., Sorrento Therapeutics Inc., Tonix Pharmaceuticals, Abwiz Bio, AXIM Biotechnologies.

North America was the largest region in the neutralizing antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neutralizing antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neutralizing antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the neutralizing antibody market by increasing the cost of imported raw materials, laboratory reagents, and bioprocessing equipment. Segments such as monoclonal antibody production and recombinant polyclonal antibodies are most impacted, with Asia-Pacific regions like China and India facing higher import duties. This has led to increased production costs and potential delays in R&D pipelines. On the positive side, tariffs have encouraged local manufacturing, investments in domestic antibody production, and innovation in cost-effective therapeutic development.

The neutralizing antibody market research report is one of a series of new reports that provides neutralizing antibody market statistics, including neutralizing antibody industry global market size, regional shares, competitors with a neutralizing antibody market share, detailed neutralizing antibody market segments, market trends and opportunities, and any further data you may need to thrive in the neutralizing antibody industry. This neutralizing antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A neutralizing antibody is a type of antibody that specifically attaches to a virus or pathogen and inhibits its ability to enter and infect host cells. Its main function is to prevent infection by neutralizing the harmful activity of the pathogen, thereby stopping or slowing disease progression.

The primary antibody types of neutralizing antibodies include monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are laboratory-engineered molecules developed to bind selectively to a single type of antigen, such as a virus or cancer cell. Neutralizing antibodies target a wide range of viruses, including SARS-CoV-2 (COVID-19), human immunodeficiency virus (HIV), influenza, Ebola, Zika, hepatitis C, and others. Distribution channels comprise direct sales to end users, distributors, online retail platforms, and other channels. Applications cover therapeutics, diagnostics, and research and development, serving end users such as hospitals and clinics, research institutions, diagnostic laboratories, pharmaceutical companies, and others.

The neutralizing antibody market consists of sales of antibody kits, reagents, and related diagnostic and therapeutic products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.